Mylan Inc. (MYL) announced that its privately held Indian subsidiary, Matrix Laboratories Ltd., has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Lansoprazole Delayed-release Capsules, 15 mg and 30 mg. Lansoprazole Delayed-release Capsules are the generic version of Tap Pharmaceuticals' proton pump inhibitor Prevacid DR Capsules.
The company said the product is shipping immediately and will be sold under the Mylan Pharmaceuticals brand.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.